Business
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross ProceedsPRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today the Company received aggregate gross proceeds of $1.6 million from the exercise of 1,417,208 Series A Right Warrants at $1.13 per warrant upon their
About this update from Cytosorbents Corporation
[{"type":"image","alt":"CytoSorbents","displaySize":"","headline":null,"caption":"CytoSorbents","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6f8e543060d285e6665e0099179bd28f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z3w.zWE9Htdhk1dO6q.XQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6f8e543060d285e6665e0099179bd28f","width":300,"height":157}},"lazy":false},{"type":"text","content":"1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds","length":114,"tagName":"p"},{"type":"text","content":"PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today the Company received aggregate gross proceeds of $1.6 million from the exercise of 1,417,208 Series A Right Warrants at $1.13 per warrant upon their expiration at 5:00 PM EST on February 24, 2025. The Series A Right Warrants were exercised by shareholders, including members of the Company’s management and Board of Directors, who received them as part of the Company’s previously closed Rights Offering (the “Rights Offering”).","length":666,"tagName":"p"},{"type":"text","content":"The Company has now raised a total of $7.85 million of aggregate gross proceeds, inclusive of the original $6.25 million raised on January 10, 2025, through the exercise of subscription rights and the exercise of Series A Right Warrants. As previously disclosed, the proceeds from the January 10, 2025 Rights Offering also satisfied a debt covenant allowing for $5.0 million of restricted cash on our balance to become unrestricted and available for use. As a result, the Company’s balance sheet has been strengthened with an increase of net liquidity available to the Company of approximately $12.3 million, net of related offering fees.","length":638,"tagName":"p"},{"type":"text","content":"“We are pleased with the success of our Rights Offering which has served to strengthen our balance sheet and provide the liquidity to drive innovation and execution in our core international business with CytoSorb® while we pursue potential U.S. and Canadian approval ...